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The body has the capacity to compensate for an
occluded artery by creating a natural bypass upon
increased fluid shear stress. How this mechanical
force is translated into collateral artery growth (arte-
riogenesis) is unresolved. We show that extravasa-
tion of neutrophils mediated by the platelet receptor
GPIba and uPA results in Nox2-derived reactive oxy-
gen radicals, which activate perivascular mast cells.
These c-kit+/CXCR-4+ cells stimulate arteriogene-
sis by recruiting additional neutrophils as well as
growth-promoting monocytes and T cells. Addition-
ally, mast cells may directly contribute to vascular re-
modeling and vascular cell proliferation through
increased MMP activity and by supplying growth-
promoting factors. Boosting mast cell recruitment
and activation effectively promotes arteriogenesis,
thereby protecting tissue from severe ischemic
damage. We thus find that perivascular mast cells
are central regulators of shear stress-induced arte-
riogenesis by orchestrating leukocyte function and
growth factor/cytokine release, thus providing a
therapeutic target for treatment of vascular occlusive
diseases.INTRODUCTION
Arteries transport oxygenated blood from the heart to every
individual organ of the body. Accordingly, occlusion of a majorCell Re
This is an open access article under the CC BY-Nartery by thrombus formation or stenosis results in substantially
reduced perfusion of distal organs, leading to ischemic damage
or even necrosis of the affected tissue. Current options to treat
vascular occlusive diseases such as myocardial infarction,
stroke, or peripheral artery disease are percutaneous translumi-
nal angioplasty (PTA) or bypass surgery. However, the body can
create natural bypasses from pre-existing arteriolar anastomo-
ses. This so-called arteriogenesis constitutes a tissue and
even life-saving process, as it can compensate for the loss of a
major peripheral or coronary artery. Promoting arteriogenesis
in ischemia-related diseases may present a non-invasive alter-
native therapeutic approach to established clinical interventions.
Arteriogenesis is a complex, multi-factorial process (Deindl
and Schaper, 2005) that involves the proliferation of endothelial
cells (ECs) and smooth muscle cells (SMCs) as well as the
recruitment of leukocytes, especially monocytes, which provide
a variety of growth-promoting factors to the growing blood
vessel (Arras et al., 1998). It is, therefore, not surprising that
the therapeutic use of single growth factors or cytokines to sup-
port arteriogenesis did not meet expectations in clinical studies.
To effectively promote arteriogenesis in patients, it is important
to identify the molecular mechanisms naturally triggering the
process of collateral artery growth.
Mast cells reside in the perivascular space of arteries (Wolf
et al., 1998) and produce several vasoactive substances and
growth factors (Hiromatsu and Toda, 2003; Rao and Brown,
2008), some of which have been described to contribute to arte-
rial remodeling (Cao et al., 2003; Ito et al., 1997). The functional
role of these c-kit+/CXCR4+ cells in arteriogenesis is currently
unclear. Moreover, how fluid shear stress, which is the driving
force for arteriogenesis (Pipp et al., 2004) and is sensed directly
by vascular ECs, is translated into the activation of perivascular
mast cells remains unresolved. Here we dissect the underlyingports 16, 2197–2207, August 23, 2016 ª 2016 The Author(s). 2197
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Collateral Artery Growth Is Fostered by Activated Mast Cells
(A) Photographs of superficial collateral arteries (arrows) in the medial adductor hindlimb region of a mouse. Right: pre-existing collaterals on the left sham-
operated leg are observed as thin vessels running in a straight line. Left: grown collateral arteries of the occluded right leg (occ) have drastically increased in
diameter and appear in a typical corkscrew formation. Pictures were taken 21 days after the surgical procedure. Scale bar, 1 mm; n = 3.
(B) Representative Giemsa staining reveals mast cell degranulation next to growing collaterals (arrow left), whereas sham operation had no effect on mast cells
(arrows right). Pictures were taken 3 days after the surgical procedure. Scale bar, 100 mm; n = 6.
(C) Mast cell degranulation is shown per collateral 2 hr, 12 hr, 24 hr, and 3 days after fal (n = 4 animals with four collaterals/time point; *p% 0.05 from two-way
ANOVA with Newman-Keuls test).
(D) Laser Doppler perfusion measurements of wild-type mice following fal (right leg) and sham operation (left leg). Upper panels: perfusion was calculated by
means of laser Doppler right-to-left ratios before, immediately after, and at 6, 12, 24, and 48 hr (middle panel) or at days 3, 7, 14, and 21 after the surgical
procedure (right and left panels). Color-coded lines indicate treatment of mice (control = saline). Control and internal control (dipA) of the right plot are identical to
that of the left plot. Statistical analysis (p % 0.05) was performed between different groups (n = 6 per group) using repeated-measures two-way ANOVA with
subsequent multiple comparisons by Bonferroni test (&C48/80 versus control; YdipA versus control; NSCF versus control; *C48/80 + dipA versus control; UC48/
80 + dipA versus dipA; cC48/80 + dipA versus C48/80; Lcromolyn versus control; +cromolyn versus dipA; and fcromolyn + dipA versus dipA). Lower panels:
representative flow images of day 7 are shown.
Data are means ± SEM. See also Figure S1.mechanisms, finding a decisive role for platelets and neutrophils
in this process. In particular we find that platelet receptor
GPIba-dependent and urokinase plasminogen activator (uPA)-
mediated extravasation of neutrophils culminates in mast cell
activation by reactive oxygen species (ROS) produced by
neutrophil-expressed Nox2. Furthermore, following natural or
pharmacological activation, we find that mast cells promote
arteriogenesis by creating an inflammatory microenvironment
essential for the recruitment of growth-promoting leukocytes.
Thus, mast cells might represent a therapeutic target for the
treatment of vascular occlusive diseases.
RESULTS
Mast Cell Activation Fosters Experimental
Arteriogenesis
To study the functional impact of mast cells in arteriogenesis,
we used an experimental murine hindlimb model in which2198 Cell Reports 16, 2197–2207, August 23, 2016femoral artery ligation (fal) resulted in collateral artery growth
in the upper leg (Figure 1A) (Limbourg et al., 2009). Our results
showed that, upon fal, mast cells located in the perivascular
space of collaterals became activated and gradually but spe-
cifically degranulated (Figures 1B and 1C). Moreover, treat-
ment of mice with the mast cell activator Compound 48/80
(C48/80); the c-kit ligand stem cell factor (SCF), which triggers
mast cell maturation and recruitment (Oliveira and Lukacs,
2003); or diprotin A (dipA) (for protocols, see Figure 7 and
Supplemental Experimental Procedures), respectively, signifi-
cantly enhanced perfusion recovery upon fal (Figure 1D).
DipA treatment, inhibiting dipeptidylpeptidase IV (DPPIV) activ-
ity and, thereby, retarding stroma cell-derived factor-1 (SDF-
1a) degradation (Zaruba et al., 2009), resulted in an increased
level of SDF-1a (Figure S1A) and drastically increased the
number of c-kit+ cells (Figure S1B). In accordance with previ-
ous findings (McGowen et al., 2009), C48/80 treatment pro-
voked enhanced mast cell degranulation, culminating in a
Figure 2. C48/80 + DipA Treatment Fosters
Leukocyte Recruitment
(A) Proteolytic activity of matrix metalloproteinases
(MMPs) was measured in collaterals of mice 24 hr
after fal and saline (control) or C48/80 + dipA treat-
ment (n = 3).
(B) MCP-1 protein levels were measured in collat-
erals of mice treated with saline (control) or C48/80 +
dipA 24 hr after fal (n = 3).
(C) TNF-a levels were measured in plasma of mice
without fal (control w/o lig) or 24 hr after fal and saline
(control w lig) or cromolyn treatment (cromolyn w lig)
(n = 3 per group).
(D) Left: representative immunostaining showing
CD45-positive cells (arrows) in the perivascular
region of collaterals of saline- (control), cromolyn-,
cromolyn + dipA-, and C48/80 + dipA-treated ani-
mals 3 days after fal. Right: quantitative analysis is
shown. Scale bars, 100 mm; n = 4 animals with four
collaterals each.
(E and F) Quantitative analyses by flow cytometry
of CD45+/CD11b+/Gr-1+/CD115, CD45+/CD11b+/
F4/80+, and CD45+/CD3+ cells in adductor muscles
of mice at day 1 (E) and day 3 (F) after fal and
saline (control, open bars) or C48/80 + dipA (filled
bars) treatment (n = 6 per group; *p % 0.05 in (C)
and (D) from two-way ANOVA with Newman-Keuls
test).
Data are means ± SEM. See also Figures S2
and S3.drastic reduction in the numbers of detectable mast cells in the
vicinity of collateral arteries (93% ± 4.6% reduction, p < 0.05).
Combined administration of C48/80 and dipA further increased
perfusion recovery, reaching significant values already 6 hr
after fal (Figure 1D), whereas combined treatment of mice
with C48/80, dipA, and SCF showed no further additive effect
(Figure S1C).
Simultaneous treatment of mice with dipA and the mast cell
stabilizer cromolyn was performed to exclude the possibility
that the positive effect of dipA was not mainly due to the mobili-
zation of other bone marrow-derived cells also expressing the
SDF-1a receptor CXCR-4 (e.g., monocytes and stem cells). Cro-
molyn treatment abolished the stimulating effect of dipA and
impaired perfusion recovery (Figure 1D) to a similar extent as
observed with single cromolyn treatment (Figure 1D), indicating
that the majority of recruited cells were indeed mast cells that
promoted arteriogenesis by their degranulation products.
Cromolyn treatment also blocked the positive effect of C48/80
(Figure S1D).
Mast cell-deficient Mcpt5-Cre+ R-DTA mice showed no
reduced perfusion recovery upon the induction of arteriogenesis.
Intriguingly, these mice responded neither to cromolyn nor to
C48/80 treatment (Figure S1E). These data indicate that these
transgenic mice were capable of compensating the lack ofCell Remast cells in arteriogenesis; yet, cromolyn
as well as C48/80, specifically influenced
the action of mast cells or, if at all, did not
influence decisively other cells or off tar-gets relevant for the process of collateral artery growth in wild-
type mice.
Combined Treatment of Mice with C48/80 and DipA
Promotes Leukocyte Recruitment and Vascular Cell
Proliferation
Matrix metalloproteinases (MMPs), which are well described to
be activated by mast cell-derived proteases (Kovanen, 2007),
degrade and remove basement membrane proteins around
SMCs (Rudijanto, 2007) and have been shown to promote
vascular remodeling in the context of arteriogenesis (Cai et al.,
2000). In growing collaterals of mice treated with C48/80 +
dipA, we found significantly increased MMP activity compared
to saline-treated controls (Figure 2A).
MCP-1 and tumor necrosis factor a (TNF-a) are two cytokines
previously reported tobeofmajor relevance for leukocyte recruit-
ment in the process of arteriogenesis (Grundmann et al., 2005; Ito
et al., 1997). Heremice treatedwithC48/80+dipA showedsignif-
icantly increased mRNA and protein levels of MCP-1 compared
to saline-treatedcontrols (Figures 2BandS2). In contrast, cromo-
lyn treatment strongly reduced the plasma level of TNF-a as
compared to saline-treated controls (Figure 2C), indicating that
mast cells play a major role in providing this cytokine being rele-
vant for leukocyte recruitment (Malaviya et al., 1996).ports 16, 2197–2207, August 23, 2016 2199
Figure 3. Mast Cells Promote Vascular Cell
Proliferation and Vessel Growth
(A) Representative fluorescent immunohistological
pictures of collaterals of mice 2 hr after fal. c-kit+
cells in close proximity to collaterals (marked by
dotted lines) stain positive for FGF-2 and PDGF-BB.
Scale bar, 10 mm; n = 6 slices from three individual
experiments.
(B) Left: representative immunostaining showing
Ki67+ cells (stained in brown) in collaterals of mice
treated with saline (control), C48/80 + dipA, or cro-
molyn + dipA 3 days after fal. Right: quantitative
analysis is shown. Scale bar, 100 mm; n = 3 animals
with four collaterals each.
(C) Left: representative HE staining documenting
collaterals of mice treated with saline (control) or
C48/80 + dipA at day 3 or 7 after fal. Right: chart
shows inside luminal diameter of collaterals of mice
treatedwith saline (control) or C48/80 + dipA at day 3
and 7 after fal or sham operation.
Scale bar, 100 mm; n = 3 animals with three collat-
erals each; *p % 0.05 (B and C) from two-way
ANOVA with Newman-Keuls test. Data are means ±
SEM. See also Figure S4.Immunohistological analyses of the adductor muscle re-
vealed significantly increased numbers of CD45+ (pan leukocyte
marker) cells in the perivascular space of C48/80 + dipA-treated
mice (Figure 2D). Subset analyses of recruited CD45+ cells by
flow cytometry showed significantly increased levels of neutro-
phils (Gr-1+/CD115) and macrophages (F4/80+) at day 1 after
fal (Figures 2E and S3A) and neutrophils, macrophages, and
T cells (CD3+) at day 3 after fal (Figures 2F and S3B). The latter
represents a subset of leukocytes previously described to
invade tissue in a TNF-a-dependent manner (Maggi et al.,
2013) and to be involved in arteriogenesis (Stabile et al.,
2006). Regarding the recruitment of subsets of CD45+ cells at
day 1 and day 3 after fal, a similar although less drastic effect
was observed in mice treated with C48/80 alone (Figures S3C
and S3D).
Treatment of primary vascular ECs and SMCs with condi-
tioned medium of activated mast cells increased their prolifer-
ation rate (Figure S4). Moreover, fibroblast growth factor
(FGF)-2 and platelet-derived growth factor (PDGF)-BB was
found in mast cells located in close proximity to collateral ar-
teries (Figure 3A). A combined administration of both growth
factors previously has been described to enhance arteriogene-
sis (Cao et al., 2003). Mice treated with combined C48/80 +
dipA revealed an increased number of Ki67+ (cell proliferation
marker) vascular cells in collateral arteries (Figure 3B), which
was associated with an increased luminal diameter of these2200 Cell Reports 16, 2197–2207, August 23, 2016blood vessels (Figure 3C). In contrast,
combined treatment with cromolyn +
dipA reduced the number of Ki67+
vascular cells (Figure 3B). Altogether
these data suggest that mast cells pro-
mote vascular cell proliferation, not only
indirectly by promoting leukocyte recruit-
ment supplying growth-promoting factorsbut also by themselves representing a source of vascular
growth factors.
Boosting Mast Cell Recruitment and Activation Protects
Tissue from Damage by Fostering Arteriogenesis
Upon ligation of the femoral artery in the upper leg, the resulting
reduced perfusion of the lower leg was associated with ischemic
damage, provoking increased infiltration of leukocytes and capil-
lary sprouting (angiogenesis). Both processes are necessary for
removing fibrotic and necrotic tissue. Since our data demon-
strate that combined treatment of mice with C48/80 + dipA
significantly increased perfusion recovery already 6 hr after fal
(Figure 1D), we hypothesized that this is associatedwith reduced
damage of the distal calf muscle (Figure S5). Histological anal-
ysis of the gastrocnemius muscle revealed almost negligible
ischemic tissue damage in mice treated with C48/80 + dipA (Fig-
ure 4A). This was associated with (1) a significantly reduced infil-
tration of leukocytes (CD45+ cells) (Figure 4B) as well as (2) a
diminished capillary sprouting, as shown by the reduced number
of Ki67+ ECs (Figure 4C) and a reduced capillary-to-muscle fiber
ratio (Figure S6). Interestingly, neither fal nor local application of
C48/80 in the upper leg resulted in mast cell degranulation in the
ipsilateral lower leg (M. gastrocnemius) (Figure 4D) or in the
contralateral upper or lower leg (data not shown). These data
indicate that local application of C48/80 in the upper leg did
not result in systemic effects of the agent. Additionally, the
Figure 4. Effective Arteriogenesis Protects
Tissue from Severe Ischemic Damage
(A) Representative HE staining of gastrocnemic
muscles 3 days after fal (control) or sham operation
or 3 days after fal and C48/80 + dipA treatment
in different magnifications. Scale bar, 100 mm.
Bar graph represents ischemic tissue in the M.
gastrocnemius in percentage of high-power field.
(B) Left: representative pictures of immunostaining
show reduced infiltration of leukocytes (CD45+ cells,
arrows, stained in brown) in the M. gastrocnemius of
mice treated with C48/80 + dipA compared to
saline- (control) treated mice 3 days after fal. Scale
bar, 100 mm. Right: quantitative analysis is shown.
(C) Left: following fal, representative pictures docu-
ment Ki67-positive capillaries (arrows, stained in
brown) in theM. gastrocnemius of saline- (control) or
C48/80-treated mice 3 days after fal. Scale bar,
100 mm. Right: number of Ki67-positive capillaries
was quantified.
(D) Representative Giemsa staining of the M.
gastrocnemius of mice treated with saline (control)
or C48/80 + dipA 3 days after fal or sham operation.
Insets show magnifications of mast cells.
Scale bar, 100 mm; n = 3 in triplicates (A–D). Data are
means ± SEM. See also Figures S5 and S6.data suggest that protection of tissue from ischemic damage
was a result of arteriogenesis in the upper leg, but not due to
degranulation of mast cells in the lower leg.
Perivascular Mast Cells Are Activated by a Cascade of
Platelet- and Neutrophil-Dependent Reactions
Fluid shear stress, which is the driving force behind arteriogene-
sis, can only be sensed directly by vascular ECs, but not by peri-
vascular cells. Hence, we asked which factors or cells may be
responsible for mast cell degranulation during the initial phase
of arteriogenesis. As platelets are sensors of fluid shear stress
and can adhere to endothelial von Willebrand factor (vWF) under
conditions of increased fluid shear stress through platelet GPIbCell Rereceptor (Sadler, 2002), we hypothesized
that platelets or platelet-dependent reac-
tions may be involved in transmitting mo-
lecular signals from the vascular lumen to
the perivascular space.
Interestingly, blockage of the platelet re-
ceptor GPIba as well as genetic ablation of
the ectodomain of GPIba in transgenic IL4-
R/Iba mice inhibited mast cell degranula-
tion to a similar extent as cromolyn treat-
ment (Figure 5A). Similarly, uPA deficiency
or the inhibition of uPA proteolytic activity
by the administration of UK122 signifi-
cantly diminished mast cell degranulation
(Figure 5A).
We have shown previously that uPA defi-
ciency (but not uPA receptor or tissue plas-
minogen activator deficiency) is associated
with a reduced perfusion recovery upon fal,which was due to reduced leukocyte infiltration (day 3 after fal)
(Deindl et al., 2003). Recently, we observed a reduced reperfu-
sion recovery upon fal when blocking the GPIba receptor using
a Fab fragment. Furthermore, the same effect was seen in GPIba
receptor-deficient IL4-R/Ibamice. Of note, our results evidenced
that the GPIba receptor is essential in arteriogenesis for (1) tran-
sient platelet interaction with collateral endothelium, (2) differen-
tial expression of vascular uPA (day 1 after fal), (3) platelet-
neutrophil aggregate (PNA) formation (day 1 after fal), and (4)
extravasation of leukocytes (3 days after fal) (Chandraratne
et al., 2015). Furthermore, in a model of hepatic ischemia
reperfusion injury, we found endothelial-derived uPA to be
essential for intravascular adherence of neutrophils. Moreover,ports 16, 2197–2207, August 23, 2016 2201
Figure 5. Mast Cells Are Activated by Neutrophil-Derived ROS
(A) Degranulated mast cells in the perivascular space of collaterals 1 day after fal in control mice or in mice treated with cromolyn to stabilize mast cells; UK122
(uPA inhibition); 1A8 (neutrophil-depleting agent); N-actelcysteine (NAC, ROS scavenger); apocynin (NADPH oxidase inhibitor); GPIba-blocking Fab fragment;
isotype Fab fragment; and in mice deficient for platelet receptor GPIba (IL4-R/Iba mice), uPA, or Nox2, respectively, are shown (n = 4 animals with two collaterals
each).
(B and C) Flow cytometry analysis of CD45+/CD11b+/Gr-1+/CD115 and CD45+/CD11b+/F4/80+ cells in adductor muscles of animals treated with GPIba-
blocking Fab fragment or isotype Fab fragment (B) or uPA inhibitor UK122 or control group (C) at day 1 after fal is shown (n = 4).
(D) Laser Doppler perfusion measurements of (left panel) wild-type mice (control), Nox2-deficient mice (Nox2/), wild-type mice reconstituted with bone
marrow from wild-type mice (controlcontrol), and wild-type mice reconstituted with bone marrow from Nox2-deficient mice (controlNox2/) and (right panel) wild-
type mice (control), Nox2-deficient mice reconstituted with bone marrow from Nox2-deficient mice (Nox2/Nox2/), and Nox2-deficient mice reconstituted
with bone marrow fromwild-type mice (Nox2/control) after the induction of arteriogenesis (right leg) or sham operation (left leg) at the indicated time points after
the surgical procedure. Color-coded lines indicate different groups. The controls of the left and right plot are identical. Statistical analysis (p % 0.05) was as
follows: *Nox2/ versus control; FcontrolNox2/ versus control; &Nox2/ versus controlcontrol; UcontrolNox2/ versus controlcontrol; ccontrolNox2/ versus
Nox2/; #Nox2/Nox2/ versus control; εNox2/Nox2/ versus Nox2/control; and %Nox2/control versus control (n = 5 per group).
(E) Degranulated mast cells in the perivascular space of growing collaterals 1 day after fal in Nox2/control, Nox2/Nox2/, controlNox2/, and controlcontrol
mice are shown (n = 6 slices from three individual animals with two collaterals each).
(F) Laser Doppler perfusion measurements of saline- (control), 1A8-, or 1A8 + C48/80-treated wild-type mice following fal (right leg) and sham operation (left leg)
(n = 6 per group). Statistical analysis (p% 0.05) was as follows: &control versus 1A8 and *1A8+C48/80 versus 1A8.
Data are means ± SEM. Significances (*p% 0.05) in (A) and (E) were from two-way ANOVA with Newman-Keuls test, and significances in (D) and (F) were from
repeated-measures two-way ANOVA with subsequent multiple comparisons by Bonferroni test. See also Figure S7.neutrophil-derived uPA was critical for subsequent paracellular
transmigration of neutrophils and, hence, extravasation (Reichel
et al., 2011). We therefore hypothesized that neutrophils also
may play a role in arteriogenesis and may represent the missing
link inmast cell activation. Indeed, inhibition of GPIba receptor or
uPA activity resulted not only in reduced mast cell activation but
also in diminished neutrophil infiltration at day 1 after fal, as as-
sessed by flow cytometry (Figures 5B and 5C).
To analyze the functional relevance of neutrophils and PNA
formation in more detail, we performed in vitro studies using iso-
lated platelets and neutrophils. We found that PNA formation is a
prerequisite for surface expression of uPA on neutrophils as well2202 Cell Reports 16, 2197–2207, August 23, 2016as for extracellular superoxide anion formation (Figures S7A–
S7D). P-selectin deficiency on platelets as well as deficiency of
its ligand PSGL-1 on neutrophils interfered with PNA formation
and diminished uPA surface expression (Figures S7A–S7C). In
addition, P-selectin deficiency of platelets prevented superoxide
anion formation (Figure S7D), accounting for the relevance of
platelet P-selectin for the production of neutrophil-derived
ROS (Page and Pitchford, 2013). Finally, extracellular ROS pro-
duction was absent when using Nox2-deficient neutrophils for
PNA formation, indicating that neutrophils are the source of su-
peroxide anions (Figure S7D). A proposed model for neutrophil
activation during arteriogenesis is shown in Figure S7E.
Figure 6. Proposed Model for the Central Role of Mast Cells in
Arteriogenesis
Step 1. Upon occlusion of a main artery, increased fluid shear stress
in collateral arteries initiates GPIba-dependent PNA formation, which results
in the activation of neutrophils. Step 2. After uPA-mediated extravasation
of neutrophils, Nox2-derived superoxide anions (ROS) induce mast cell
degranulation. Step 3. TNF-a promotes further neutrophil extravasation in a
positive feedback loop. Step 4. TNF-a supports T cell extravasation and
MCP-1 attracts monocytes, which mature to macrophages and supply the
growing vessel with growth factors and cytokines. See also Figure S7E.To assess whether Nox2-derived ROS from neutrophils are
relevant for mast cell degranulation during arteriogenesis, we
performed further in vivo analyses. Indeed, our results showedthat depletion of neutrophils by the application of 1A8 (reduction
of neutrophils: 70% ± 3.7%, p < 0.05), deficiency of Nox2
(= gp91phox), as well as blocking ROS production or their
function by the administration of apocynin or N-acetylcysteine
(NAC) (Schulz et al., 2014; Tobar et al., 2010), respectively,
blocked mast cell degranulation to a similar degree as observed
in GPIba-deficient mice (Figure 5A). To investigate whether
neutrophil-derived ROS are responsible for mast cell degranula-
tion, we created chimeric mice by transplanting bone marrow
from Nox2/ mice to wild-type mice (controlNox2/) and vice
versa (Nox2/control). Compared to their corresponding control
(controlcontrol), controlNox2/ showed a significant reduction in
perfusion recovery as well as mast cell degranulation, whereas
Nox2/control revealed a significant improvement in collateral
formation as compared to control (Nox2/Nox2/) (Figures
5D and 5E). To confirm that mast cells become activated
by ROS derived from neutrophils, neutropenic mice were chal-
lenged with C48/80 to induce mast cell degranulation. While
neutrophil depletion impaired perfusion recovery after fal, the
induction of mast cell degranulation completely restored the
phenotype (Figure 5F).
DISCUSSION
In this study, we show that natural bypass growth is a matter of
innate immunity, and we highlight the central role of mast cells in
orchestrating leukocyte function in this process. In addition, we
deciphered the mechanisms responsible for the translation of
increased fluid shear stress to the activation of perivascular
mast cells (Figure 6).
Mast cells were found to reside in the perivascular space of
growing collaterals (Wolf et al., 1998). However, their function
in arteriogenesis has never been investigated. Moreover, the
mechanism by which perivascular mast cells become activated
by increased mechanical load, such as fluid shear stress, has
not been resolved up to now. We demonstrate that this is medi-
ated by platelets and neutrophils and that neutrophil-derived
ROS are the driving force for mast cell activation.
Fluid shear stress, which stimulates arteriogenesis, is well
described to induce the adherence of platelets to ECs, a process
mediated by the interaction of the platelet receptor GPIba with
the endothelial vWF (Sadler, 2002). We recently demonstrated
that platelet receptor GPIba is essential for the transient interac-
tion of platelets to collateral endothelium, PNA formation, and
extravasation of leukocytes during arteriogenesis (Chandraratne
et al., 2015). Here we show that platelet receptor GPIba is partic-
ularly relevant for neutrophil extravasation. We demonstrate that
PNA formation through platelet P-selectin and neutrophil PSGL-
1 is associated with uPA release to the neutrophil cell surface,
paving the way for leukocyte infiltration. Moreover, we found
that PNA formation is a prerequisite for neutrophil Nox2-depen-
dent superoxide anion release.
As the deficiency or inhibition of uPA resulted in diminished
neutrophil extravasation and mast cell degranulation, it is fair
to deduce that the activation of neutrophils through interaction
with platelets not only drives extravasation of these cells via
uPA but also promotes mast cell activation via the release of
neutrophil superoxide anions. This conclusion is endorsed byCell Reports 16, 2197–2207, August 23, 2016 2203
our findings showing (1) a rescue of the impaired reperfusion re-
covery and mast cell degranulation observed in Nox2/ mice
by the transplantation of bone marrow isolated from wild-type
mice, and (2) restored perfusion in neutropenic mice by the in-
duction of mast cell degranulation. These in vivo data are af-
firmed by in vitro findings showing that ROS stimulate mast
cell activation (Gan et al., 2015) as well as by our results showing
that activated neutrophils induce mast cell degranulation (Fig-
ure S7F). Together, these data indicate that the intravascular,
shear stress-dependent activation of platelets and PNA forma-
tion triggers the production of effectors, such as ROS, that serve
to transmit the locally initiated signal to proximal perivascular
sites where mast cell degranulation is initiated.
Interestingly enough, platelet activation, uPA-mediated
neutrophil extravasation, as well as mast cell activation recently
were shown to contribute to reperfusion injury due to revascular-
ization or organ transplantation (Chang et al., 2014; Egashira
et al., 2013; Ko¨hler et al., 2011; Reichel et al., 2011; Yang
et al., 2014). In addition, allergic contact dermatitis was reported
to strongly depend on mast cells, neutrophils, and neutrophil-
derived ROS (Weber et al., 2015). Thus, the mechanisms identi-
fied in this study for mast cell activation under arteriogenic con-
ditions appear to have a strong andmore general impact, not just
on pathogenesis and control of cardiovascular diseases, and
they will contribute to the understanding of mast cell-dependent
pathways in sterile inflammation/innate immunity.
In our study, we found mast cells to specifically degranulate
around growing collateral arteries. Additional pharmacological
activation of mast cells with C48/80 greatly enhanced perfusion
recovery and, hence, arteriogenesis. Stabilizing mast cells with
cromolyn showed the opposite effect and blocked the positive
effect of C48/80 as well as dipA. Mast cell-deficient Mcpt5-
Cre+ R-DTA mice showed no reduced perfusion recovery
upon fal, neither was it improved by C48/80 treatment nor
impaired by cromolyn. These data suggest that these trans-
genic mice were capable of compensating the lack of mast cells
in the process of arteriogenesis and that cromolyn as well as
C48/80 specifically and decisively influenced the action of
mast cells in the process of collateral artery growth in wild-
type mice.
TNF-a is a major determinant in neutrophil recruitment, as evi-
denced in many experimental settings (Griffin et al., 2012; Mala-
viya et al., 1996). Our results demonstrate that inhibition of mast
cell degranulation strongly reduced the elevated plasma levels of
TNF-a observed upon the induction of arteriogenesis. C48/80
treatment, in contrast, resulted in an increased number of neu-
trophils, especially at day 1 after fal (Figure S3C). These data
indicate that neutrophils are likely to be recruited by mast cells
in a positive feedback mechanism. Our data are in line with pre-
vious results showing mast cells to be essential for elevated
TNF-a levels and neutrophil recruitment (Malaviya et al., 1996;
Sun et al., 2007). TNF-a also has been implicated in MCP-1 pro-
duction (Murao et al., 2000), relevant for monocyte recruitment
(Ito et al., 1997). In our study, boosting mast cell activation
by C48/80 resulted in increased levels of macrophages and
T cells, particularly at day 3 after fal. Recruitment of perivascular
macrophages supplying growth factors to growing blood vessels
(Arras et al., 1998) was demonstrated to be essential for arterio-2204 Cell Reports 16, 2197–2207, August 23, 2016genesis (Heil et al., 2002; Hoefer et al., 2004; Ito et al., 1997),
whereas T cells have been described to contribute to macro-
phage recruitment (Stabile et al., 2003). Hence, mast cells indi-
rectly promoted arteriogenesis by amplifying the inflammatory
reaction, thus providing macrophage-derived growth factors
supporting vascular cell proliferation. In addition, mast cells
may directly contribute to vascular cell proliferation as shown
by our in vitro results.
In a more translational approach, we administrated dipA,
which again increased perfusion recovery. Platelets, which tran-
siently adhere to the endothelium of growing collaterals in the
early phase of arteriogenesis (Chandraratne et al., 2015), are a
rich source of SDF-1a. Platelet activation enhances surface
expression and release of SDF-1a (Chatterjee and Gawaz,
2013), which results in recruitment of CXCR-4+ cells at the site
of inflammation. The administration of dipA, blocking DPPIV
activity and, hence, SDF-1a degradation, resulted in a drastic in-
crease in the number of c-kit+ mast cells together with a signifi-
cantly improved perfusion recovery.
Combined treatment of mice with C48/80 and dipA showed
additive effects in terms of perfusion recovery and leukocyte
recruitment, and it protected tissue from severe ischemic dam-
age by effectively promoting arteriogenesis. Although we found
that leukocytes, which express the SDF-1a receptor CXCR-4
aswell, are recruited upon dipA treatment, a substantial increase
in leukocyte recruitment occurred not earlier than upon treat-
ment with dipA in combination with C48/80 (Figure 2D), arguing
for the relevance of mast cells in this process.
Mast cells express the SDF-1a receptor CXCR-4 aswell as the
SCF receptor c-kit. Both ligands have been addressed in many
experimental as well as clinical settings to recruit stem cells aim-
ing at promoting neovascularization. Since it has been demon-
strated previously that bone marrow-derived stem cells do not
differentiate to ECs or SMCs and, hence, do not contribute to
vascularization, i.e., arteriogenesis and angiogenesis (Ziegel-
hoeffer et al., 2004), our results may shed a different light on
the nature of c-kit+/CXCR-4+ stem cells recruited to sites of neo-
vascularization. Diverse studies could not demonstrate the pres-
ence of recruited stem cells at sites of (neo-) vascularization
despite a functional improvement. In this context it might be of
particular interest to mention that extensively degranulated
mast cells cannot be identified anymore as individual cells in tis-
sue (McGowen et al., 2009). A huge number of publications are
available attributing mast cells an essential role in tumor angio-
genesis; however, little information is available on the role of
mast cells under other pathological or physiological conditions
and results are contradictory.
Much effort has been made to find new therapeutic options
to treat patients with vascular occlusive diseases. Here we
show that promoting mast cell recruitment concomitant with
mast cell activation promotes the growth of natural arteriolar
bypasses to such an extent that distal tissue is preserved
from severe ischemic damage. Local administration of C48/
80 showed no systemic side effects in our study, and mast
cell activators as well as drugs that inhibit DPPIV are used in
clinical applications (Rukwied et al., 2000; Yanai, 2014). Recent
clinical studies showed no major adverse cardiovascular events
in patients with type 2 diabetes treated with DPPIV inhibitors
Figure 7. Study Protocol
Treatment protocol of mice with C48/80, SCF, dipA, or cromolyn with the indicated time points of laser Doppler perfusion measurements. Tissue for qRT-PCR
was harvested at 12 hr, for protein analyses at 24 hr, for flow cytometry analyses at days 1 and 3, and for histology or immunohistology at 2 hr, 12 hr, 24 hr, 3 days,
or 7 days after fal (right leg) or sham operation (left leg).(White et al., 2013) and evidenced a lower risk for hospitaliza-
tion for heart failure (Fadini et al., 2015), although there might
be differences depending on the DPPIV inhibitor used. There-
fore, SDF-1a, which recently has been shown in an animal
model to promote vascular outward remodeling when locally
released (Krieger et al., 2016), or DPPIV inhibitors alone or in
combination with locally applied mast cell-activating factors
may represent therapeutic approaches to treat affected pa-
tients non-invasively.
Collectively, our data show that mast cells play a central role in
arteriogenesis by converting signals derived from upstream
platelets and neutrophils in actions that specifically support the
process of collateral artery growth. Pharmacological induction
of mast cell recruitment and degranulation effectively promotes
arteriogenesis, thereby protecting tissue from severe ischemic
damage, and may thus constitute a therapeutic approach to
treat patients with vascular occlusive diseases.
EXPERIMENTAL PROCEDURES
Murine Hindlimb Model of Arteriogenesis and Bone Marrow
Transplantation
Animal care and all experimental procedures were performed in strict accor-
dance to the German and NIH animal legislation guidelines and were approved
by the Bavarian Animal Care and Use Committee (GZ. 55.2-1-54-2532-73-12).
Ligation of the right femoral artery was induced in 8- to 10-week-old male
SV129/S6 mice (Charles River Laboratories) treated with the indicated sub-
stances (for protocol see Figure 7 and the Supplemental Experimental Proce-dures); in bone marrow-transplanted mice; in Mcpt5-Cre+ R-DTA, Nox2/,
uPA/, and IL4-R/Iba mice; and in corresponding wild-type littermates,
respectively, as previously described (Limbourg et al., 2009). The left side
was sham operated and served as control. For Laser-Doppler perfusion
measurements, bone marrow transplantation, and further information, see
the Supplemental Experimental Procedures.
SDF-1a, TNF-a, and MCP-1 Quantifications
SDF-1a protein levels in serum and collaterals were analyzed using a mouse
SDF-1a ELISA kit (ELM-SDF1alpha-001-1, RayBiotech). MCP-1 and TNF-a
protein levels were analyzed with MCP-1 and TNF-a ELISA ready-SET-go
(REF 88-7391-22 and REF 88-7324-88, eBioscience), respectively, following
the manufacturer’s protocol. Plasma was collected from heparinized blood af-
ter centrifugation at 2,3003 g at 4C for 20min. Tissue was homogenized with
200 ml of cell lysis buffer (25 mM Tris [pH 7.5], 1% Triton X-100, 0.5 mM EDTA,
150 mM NaCl, 10 mM NaF, and 1% PMSF), treated five times for 2 s with
ultrasound, and centrifuged as described above. For qRT-PCR analyses of
MCP-1, see the Supplemental Experimental Procedures.
MMP Activity Assay
MMP activity in collateral samples was analyzed with SensoLyte 520 Generic
MMP Assay Kit (Anaspec). Briefly, collaterals were homogenized in assay
buffer with 0.1% (v/v) Triton X-100, centrifuged, and supernatants were incu-
bated for 2 hr with 4-aminophenylmercuric acetate (APMA) at 37C, following
the manufacturer’s protocol. Fluorescence signal was measured at excitation/
emission = 490/520 nm for 1 hr (Infinite 200, S/N 711003634, TECAN). Data
were normalized to the reference standard curve.
Histology and Immunohistology
Paraffin-embedded issue samples were isolated at the indicated time points.
After deparaffinization and antigen retrieval using Target Retrieval SolutionCell Reports 16, 2197–2207, August 23, 2016 2205
(S1699, Dako), sections were stained for CD31 (DIA-310, Dianova, dilution
1:150), Ki67 (M7249, Dako, dilution 1:100), or CD45 (550539, BD Pharmingen,
dilution 1:600), respectively. For detection of the immunoreaction, the Vectas-
tain ABC-Kit Elite Rat IgG (PK6104, Vector Laboratories) was used. DAB+
(K3468, Dako) served as chromogen for CD31 and ACE (00-1122, Invitrogen)
for Ki67 and CD45 staining. Giemsa and H&E staining were performed accord-
ing to standard procedures. The luminal diameter of collateral arterioles was
measured in at least three different sites of an individual arteriole. Cryopre-
served tissue samples were stained with an antibody against c-kit (14-1172-
85, eBioscience, dilution 1:100) and secondary antibody donkey anti-rat Cy3
(AC189C, Millipore, dilution 1:300); FGF-2 (ab106245, Abcam, dilution 1:100)
and secondary antibody donkey anti-rabbit AF488 (A21206, MoBiTec, dilution
1:100); or PDGF-BB (ab16829, Abcam, dilution 1:100) and secondary antibody
donkey anti-rabbit AF488 (A21206, MoBiTec, dilution 1:100), respectively, and
viewed with a confocal microscope (Leica SP5).
Flow Cytometry Analyses of Muscle Tissue
For flow cytometry analysis, adductor muscles were digested with 1 mg/ml
collagenase II (Biochrom) in PBS/1% BSA at 37C for 90 min. The suspension
was then filtered with PBS/2% BSA through a 70-mm cell strainer (BD Falcon),
spun for 10 min at 160 3 g, and the pellet was finally resuspended in 100 ml
PBS/2% BSA. Surface staining was conducted using CD 45 rat anti-mouse
APC-Cy7 (557659, clone 30-F11, BD Biosciences), F4/80 rat anti-mouse
eFluor 450 (48-4801, clone BM8, eBioscience), CD 115 rat anti-mouse APC
(17-1152, clone AFS98, eBioscience), CD 11b rat anti-mouse fluorescein iso-
thiocyanate (FITC) (11-0112, clone m1/70, eBioscience), GR-1 rat anti-mouse
PE (553128, clone RB6-8C5, BD Biosciences), c-kit (CD117) rat anti-mouse
PerCP/Cy5.5 (105823, clone 2B8, BioLegend), and CD3 rat anti-mouse eFlour
450 (48-0032, clone 17A2, eBioscience). Rat isotype controls were as follows:
IgG2b APC-Cy7 (552773, clone A95-1, BD Biosciences), IgG2a eFluor 450
(48-4321, clone eBR2a, eBioscience), IgG2a APC (17-4321, clone eBR2a,
eBioscience), IgG 1 FITC (11-4301, clone eBRG1, eBioscience), IgG2b PE
(553989, clone A95-1, BD Biosciences), and IgG2a PerCP/Cy5.5 (45-4321,
clone eBR2a, eBioscience). Becton Dickinson fluorescence-activated cell
sorting (FACS) lysing solution was used to fix and lyse the samples according
to the manufacturer’s protocol. Samples were measured using Gallios flow
cytometer and analyzed with Kaluza Software (both from Beckman Coulter
Genomics).
In Vitro Analyses
For protocols of the in vitro analyses, see the Supplemental Experimental
Procedures.
Statistical Analysis
Comparisons between groups were calculated by unpaired Student’s t test
unless otherwise stated. Results were considered to be statistically significant
at *p% 0.05. Data are represented as means ± SEM. Statistical analyses were
performed with GraphPad software PRISM6.
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